BORTEZOMIB SUN 3.5 mg, powder for solution for injection bottle, 10 ml
Active ingredients: Bortezomib, ESTER BORONIQUE DE MANNITOL
Commercialized according to BDPMDispensing in France: Prescription only
Powder for solution for injectionbottle, 10 mlintraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BORTEZOMIB SUN 3,5 mg, poudre pour solution injectable
- Pharmaceutical form
- poudre pour solution injectable
- Route of administration
- intraveineuse;sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 10 ml
- Marketing authorisation holder
- SUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Jan 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61180933CIP73022816CIP133400930228166Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ESTER BORONIQUE DE MANNITOLpoudre | — | SA |
| BORTÉZOMIBpoudre | 3,5 mg · un flacon | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.